Navigation Links
Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
Date:2/24/2009

ce.com

About Novartis Option Fund

The Novartis Option Fund is part of the Novartis Venture Funds. Established in 1996, the Novartis Venture Funds currently manage over US$650 million in committed capital and are invested globally in more than 50 private life sciences companies across therapeutics, vaccines, devices and diagnostics. As a financially driven corporate life science investor, the Novartis Venture Fund invests in those companies which have the potential to lead the next innovation wave in new areas that will be critical to patient care. The Novartis Venture Funds team of eight investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital.

    For more information:http://www.venturefund.novartis.com

    Contact Information:

    Heptares Therapeutics Ltd
    Dr Malcolm Weir
    Phone: +44(0)20-8906-7182
    Mobile: +44(0)7968-947268
    E-mail: malcolm.weir@heptares.com

    Clarus Ventures
    Dr Michael Steinmetz
    Phone: +1-617-949-2200
    E-mail: msteinmetz@clarusventures.com

    MVM Life Science Partners
    Dr Martin Murphy
    Phone: +44(0)20-7557-7500
    E-mail: martinmurphy@mvmlifescience.com

    Novartis Option Fund
    Dr Anja Koenig
    Phone: +41-61-3241287
    E-mail: anja.koenig@novartis.com

    Citigate Dewe Rogerson (for Heptares)
    Dr Mark Swallow
    Phone: +44(0)20-7282-2948
    E-mail: mark.swallow@citigatedr.co.uk



'/>"/>
SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Northwest Biotherapeutics Secures $700,000 Equity Financing
3. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
4. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... WASHINGTON, D.C., September 16, 2014 --The emerging field ... portable to the next level, enabling the construction ... highly efficient devices, individual molecules would take on ... and transistors. , A team of researchers from ... potential candidate for use in small-scale electronics: a ...
(Date:9/16/2014)... 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... been shown to be effective in animal models following ... to intravenous infusions that could pave the way for ... presented yesterday at the Heart Failure Society of America,s ... Las Vegas . The research, ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... the University of Pennsylvania have developed nanowires capable ... retrieving that data a thousand times faster than ... and micro-drives, all using less power and space ... professor in the Department of Materials Science and ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading China-based ... biopharmaceutical,products, will present at the UBS Global Life ... 2007 at 10:30 AM EST. The presentation ... on the Events,section of the investors page of ...
... Sept. 17 Warner Chilcott,Limited (Nasdaq: WCRX ) ... non-final Action Closing Prosecution from the U.S. Patent and,Trademark ... a,reexamination of LEO,s US Patent No. 6,753,013 (the "013 ... The 013 Patent covers TACLONEX,and certain of LEO,s products ...
Cached Biology Technology:Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Coral growth rate plummets in 30-year comparison 2Sharks' skin has teeth in the fight against hospital superbugs 2Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... must account for the complexity of the human impact ... and temporal scales. "Scale-sensitive research" emerges as a new, ... analyses, and tools to the scale in which these ... that the decisions they take resolve ecological problems at ...
... role in successful foraging for southern elephant seals, a ... the open access journal PLOS ONE ., The ... the diving behaviour of four female southern elephant seals ... with light detectors. The researchers found that increased bioluminescence ...
... www.ucr.edu ) Researchers at the University of California, ... and Technology (CE-CERT) are working with the state of ... renewable biofuels. This research supports several California legislative ... of renewable fuels and reduce greenhouse gases. These include ...
Cached Biology News:Scientists call policy-makers to be scale-aware 2Scientists call policy-makers to be scale-aware 3UC Riverside developing biofuel formulations for California 2UC Riverside developing biofuel formulations for California 3
... is a personal desktop unit ideal for use ... , Rotation speed set at 12 rpm ... C , Bottle capacity of four 35 ... ml conical ,plastic bottles , Consistent, repeatable ...
... The SC250 Express is the latest edition ... SC250 Express has an extra large diameter ... The digital display panel allows precise setting ... Large chamber for handling large quantities and ...
... a no-frills, basic SpeedVac concentrator designed for ... this unit still features a standard Teflon ... of time and heat. It is designed ... a wide variety of different rotors for ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: